Pharmacokinetics and 48-Week Safety and Efficacy of Raltegravir for Oral Suspension in Human Immunodeficiency Virus Type-1-Infected Children 4 Weeks to 2 Years of Age.

MLA

Nachman, Sharon, et al. “Pharmacokinetics and 48-Week Safety and Efficacy of Raltegravir for Oral Suspension in Human Immunodeficiency Virus Type-1-Infected Children 4 Weeks to 2 Years of Age.” Journal of the Pediatric Infectious Diseases Society, vol. 4, no. 4, Dec. 2015, pp. e76–83. EBSCOhost, https://doi.org/10.1093/jpids/piu146.

APA

Nachman, S., Alvero, C., Acosta, E. P., Teppler, H., Homony, B., Graham, B., Fenton, T., Xia Xu, Rizk, M. L., Spector, S. A., Frenkel, L. M., Worrell, C., Handelsman, E., & Wiznia, A. (2015). Pharmacokinetics and 48-Week Safety and Efficacy of Raltegravir for Oral Suspension in Human Immunodeficiency Virus Type-1-Infected Children 4 Weeks to 2 Years of Age. Journal of the Pediatric Infectious Diseases Society, 4(4), e76–e83. https://doi.org/10.1093/jpids/piu146

Chicago

Nachman, Sharon, Carmelita Alvero, Edward P. Acosta, Hedy Teppler, Brenda Homony, Bobbie Graham, Terence Fenton, et al. 2015. “Pharmacokinetics and 48-Week Safety and Efficacy of Raltegravir for Oral Suspension in Human Immunodeficiency Virus Type-1-Infected Children 4 Weeks to 2 Years of Age.” Journal of the Pediatric Infectious Diseases Society 4 (4): e76–83. doi:10.1093/jpids/piu146.